Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144780 · ClinicalTrials.gov registry record
Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 10
- Enrollment target
NCT01144780: Clinical Trial study, sponsored by Stanford University.
NCT01144780 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144780 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The objective of this study is to better understand the underlying pathogenetic mechanisms of myeloproliferative disorders (MPDs). We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-06 |
Why NCT01144780 stopped before completion
NCT01144780 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01144780 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01144780 about?
NCT01144780 is a clinical study titled "Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry". The objective of this study is to better understand the underlying pathogenetic mechanisms of myeloproliferative disorders (MPDs). We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cell...
What is the current status of trial NCT01144780?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2009-09. Estimated completion is 2012-06.
Who is sponsoring clinical trial NCT01144780?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia